Yuichi Iwaki
Founder bei MEDICINOVA, INC.
Vermögen: 2 Mio $ am 31.03.2024
Profil
Yuichi Iwaki is the founder of MediciNova, Inc. (founded in 2000) where he currently holds the title of President, Chief Executive Officer & Director.
He is also currently the Chief Executive Officer at Avigen, Inc. since 1994, the Director-Transplantation Immunology at the University of South Carolina School of Medicine since 1992, and a Professor at the University of Southern California.
Previously, he served as the Chairman & Acting Chief Executive Officer at AMCOL International Corp., a Director at Antyra, Inc., and a Professor at the University of Pittsburgh School of Medicine from 1989 to 1991.
Dr. Iwaki obtained his doctorate degree from Sapporo Medical University School of Medicine.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
MEDICINOVA, INC.
2,23% | 09.01.2024 | 1 091 933 ( 2,23% ) | 2 Mio $ | 31.03.2024 |
Aktive Positionen von Yuichi Iwaki
| Unternehmen | Position | Beginn |
|---|---|---|
| MEDICINOVA, INC. | Founder | 26.09.2000 |
Avigen, Inc.
 Avigen, Inc. Medical SpecialtiesHealth Technology Avigen, Inc. produces and sells drugs, animal health products, and chemicals. The firm also develops and commercializes small molecules of therapeutics and biologics for use in the treatment of serious neurological and neuromuscular disorders. The company was founded in 1992 and is headquartered in La Jolla, CA. | Chief Executive Officer | 18.12.2009 |
| University of South Carolina School of Medicine | Corporate Officer/Principal | 01.01.1992 |
University of Southern California
 University of Southern California Other Consumer ServicesConsumer Services University of Southern California is a private research university that mainly offers undergraduate, graduate & other higher education. The university was founded in 1880 and is headquartered in Los Angeles, CA. | Corporate Officer/Principal | - |
Ehemalige bekannte Positionen von Yuichi Iwaki
| Unternehmen | Position | Ende |
|---|---|---|
| University of Pittsburgh School of Medicine | Corporate Officer/Principal | 01.01.1991 |
Antyra, Inc.
 Antyra, Inc. Pharmaceuticals: MajorHealth Technology Antyra, Inc. develops cancer therapeutics. Its products include lead programs, a program to generate and develop disease-specific therapeutics; oncology leads, such as IGF-1R Antagonist, which represent a clinical strategy for the treatment of pancreatic and other cancers; and ANT-G12, a technology that isolates cytotoxic peptimetics that bind to cell surface targets expressed in a disease-specific context. The company was founded by by John K. A. Prendergast and Arthur J. Blume in 1996 and is headquartered in Edison, NJ. | Director/Board Member | - |
| AMCOL INTERNATIONAL CORPORATION | Chairman | - |
Ausbildung von Yuichi Iwaki
| Sapporo Medical University School of Medicine | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| MEDICINOVA, INC. | Health Technology |
| Private Unternehmen | 3 |
|---|---|
AMCOL International Corp.
 AMCOL International Corp. Construction MaterialsNon-Energy Minerals AMCOL International Corp. produces value-added, specialty minerals, and related product. The company was founded on December 30, 1959 and is headquartered in Hoffman Estates, IL. | Non-Energy Minerals |
Avigen, Inc.
Avigen, Inc. Medical SpecialtiesHealth Technology Avigen, Inc. produces and sells drugs, animal health products, and chemicals. The firm also develops and commercializes small molecules of therapeutics and biologics for use in the treatment of serious neurological and neuromuscular disorders. The company was founded in 1992 and is headquartered in La Jolla, CA. | Health Technology |
Antyra, Inc.
Antyra, Inc. Pharmaceuticals: MajorHealth Technology Antyra, Inc. develops cancer therapeutics. Its products include lead programs, a program to generate and develop disease-specific therapeutics; oncology leads, such as IGF-1R Antagonist, which represent a clinical strategy for the treatment of pancreatic and other cancers; and ANT-G12, a technology that isolates cytotoxic peptimetics that bind to cell surface targets expressed in a disease-specific context. The company was founded by by John K. A. Prendergast and Arthur J. Blume in 1996 and is headquartered in Edison, NJ. | Health Technology |
